Safety of tralokinumab in atopic dermatitis

Br J Dermatol. 2023 Mar 30;188(4):e25-e26. doi: 10.1093/bjd/ljad007.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Asthma*
  • Dermatitis, Atopic* / drug therapy
  • Humans
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • tralokinumab
  • Antibodies, Monoclonal